Peter Marks joins former FDA colleague, Rachael Anatol at Eli Lilly, becoming the second agency worker the pharma has snapped ...

The growing strength of China’s drug pipelines has gone hand-in-hand with a steep uptick in big pharma licensing deals.

To address this, many warehouse operations managers are turning to automation, including robotics, to reduce the strain on ...

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at ...

Oragenics has announced a strategic collaboration with Receptor.AI to expedite the development of a new pharmaceutical ...

Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA) ...

The completion of the Series A marks a fast-moving year for Trogenix, which only emerged from stealth in November 2024. The ...

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m ...

Eli Lilly announced the data from the OLE trial of Omvoh at United European Gastroenterology (UEG) Week in Berlin. Image ...

The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.

Through the FDA's ANDA scheme, drug manufacturers who test and produce their generic medicines on US soil can now seek ...